Placebo News and Research

RSS

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

Enrollment complete in Advaxis ADXS-HPV Phase II CIN study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed enrollment of the first 40 subject cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

12 Jul 2011

Ivermectin cream demonstrates activity against head lice eggs

In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.

11 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

Autologous adult stem cells reduce frequency of angina episodes

New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).

From Baxter International Inc. 8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Experiment to protect astronauts from bone loss during space travel

Astronauts lose a significant amount of bone mass during space travel and with long duration flights there is concern that this bone loss could lead to an increased risk of fractures.

7 Jul 2011

Natural vitamin E may reduce brain damage after stroke

Ten weeks of preventive supplementation with a natural form of vitamin E called tocotrienol in dogs that later had strokes reduced overall brain tissue damage, prevented loss of neural connections and helped sustain blood flow in the animals' brains, a new study shows.

6 Jul 2011

Former smokers with lung cancer can benefit from celecoxib treatment

Celecoxib may emerge as a potent chemopreventive agent for lung cancer, according to a recent study in Cancer Prevention Research, a journal of the American Association for Cancer Research.

6 Jul 2011

Varenicline may increase risk of adverse cardiovascular events among smokers

The use of varenicline to stop smoking is associated with a 72% increased risk of a serious adverse cardiovascular event, states an article in CMAJ.

5 Jul 2011

Women can have successful pregnancy after recurrent miscarriage

In a subset of the ALIFE study, which investigated the effect of aspirin alone or combined with low-molecular-weight heparin, compared to placebo, on the live birth rate in women with unexplained RM, the researchers looked at the length of time between the moment of randomisation to the moment of the first day of last menstruation before the subsequent pregnancy.

4 Jul 2011

Vitamin D-deficiency linked to deaths of famous musicians

Wolfgang Amadeus Mozart (27 January 1756 - 5 December 1791), suffered from many infectious illnesses including catarrh, fever, sore throat, and bad colds from 1762 to 1791, the year of his death at 35 years of age.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

30 Jun 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011